Shares of Moderna finished March 11 down by 93% from their peak in 2021. In addition to its COVID-19 vaccine, Moderna markets ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

The company's fourth-quarter revenue also included $15 million in U.S. sales of its RSV shot, which rolled out to seniors in the fall and winter after winning approval in May. It is Moderna's ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to protect adults aged 60 years and older against lower ...

Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for mRESVIA, indicated for active immunization for the ...

JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna (MRNA) to $33 from $40 and keeps an Underweight rating on the shares, primarily due to more conservative RSV and influenza ...

Feb 28 (Reuters) - Britain's health regulator said on Friday it has approved Moderna's (MRNA.O), opens ... Sign up here. RSV is a common virus that spreads very easily and causes infections ...

"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna.

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing ...